Agent for preventing and/or treating Alzheimer's disease
The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have already been confirmed actually for safety and pharmacokinetics in human, they can be a means for a pre-emptive treatment of people at risk of AD and in a stage before developing mild cognitive impairment (MCI).
1. A method for reducing Aβ42/Aβ40 ratio in the brain of a subject, comprising administering to the subject an effective amount of each of bromocriptine and topiramate,
wherein
the effective amount of each of bromocriptine and topiramate is not more than a maximum nontoxic dose of each of bromocriptine and topiramate, and
the Aβ42/Aβ40 ratio in the brain of the subject is reduced relative to the Aβ42/Aβ40 ratio in the brain of the subject in the absence of administering bromocriptine and topiramate to the subject.
2. The method according to claim 1 , further comprising administering to the subject an effective amount of cromolyn, wherein the effective amount of each of bromocriptine, topiramate, and cromolyn is a clinically-used dose of each compound.
3. The method of claim 2 , where the method is for treating Alzheimer's disease in the subject.
4. The method of claim 1 , wherein the method is for treating Alzheimer's disease in the subject.